<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>13</Volume>
				<Issue>9</Issue>
				<PubDate PubStatus="epublish">
					<Year>2012</Year>
					<Month>09</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Association of Chemotherapy-induced Leucopenia with Treatment Outcomes in Advanced Non-small-cell lung Cancer Cases Receiving the NP Regimen</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>4481</FirstPage>
			<LastPage>4485</LastPage>
			<ELocationID EIdType="pii">26876</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;b&gt;Background:&lt;/b&gt; Chemotherapy induced leutropenia has been shown to be associated with improved treatmentoutcomes in selected solid tumors. We studied the association of chemotherapy induced leutropenia with treatmentrelated outcomes in advanced non-small-cell lung cancer. &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: This is a prospective analysis of patientsreceiving chemotherapy for advanced NSCLC at the Shandong Cancer Hospital from 2005-07.The chemotherapyincluded cisplatin 35 mg/m2, IV on d1,2 and vinorelbine 25 mg/m2 IV on d1,8 every 21 days. Patients were stratifiedinto three groups (A) those experiencing grades 0 leucopenia, group (B) grades 1-2 and group (C) grades 3-4. Theoutcomes studied were response rate (RR), disease control rate (DCR), and time to progression (TTP). &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;:128 patients were studied. The RRs in groups A, B and C were 30.8%, 56.8% and 71.4%, respectively, p=0.010.The DCRs were 61.5%, 83.8% and 92.9%, respectively, p=0.009 and the median TTPs were 150 days (95%CI:91-209), 189 days (95%CI: 181-197) and 207 days (95%CI: 172-242), p=0.009. The differences in RR and TTPwere significant. In patients whose CIL kept on 10 days at least, the TTP was significantly prolonged, p=0.0213,and the same was the case for those experiencing grades 1-2 leucopenia and ECOG 0, p=0.0412. &lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;:Occurrence of CIL correlated with RR and TTP in patients with advanced NSCLC receiving cisplatin andvinorelbine chemotherapy, especially in patients experiencing grades 1-2 leucopenia and ECOG 0, and thesame for those with CIL persisting for 10 days at least. CIL could be a biological measure of drug activity anda marker of efficacy.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Chemotherapy</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">leucopenia</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Efficacy</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">non-small-cell lung cancer</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_26876_9abda526e17d9c89ba1b7a6631c35528.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
